{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:19:24Z","timestamp":1790936364954,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":3735,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1999,2]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> This study focused on the efficacy of IDEC\u2010C2B8 (chimeric anti\u2010CD20) immunotherapy relative to specific subtypes of low\u2010grade lymphoproliferative disorders\/non\u2010Hodgkin's lymphomas (LPD\/NHL). Forty\u2010eight patients with resistant or relapsed disease completed the IDEC\u2010C2B8 infusion schedule of 375 mg\/m<jats:sup>2<\/jats:sup>\/wk \u00d7 4 wk. The LPD\/NHL subtypes included: (a) follicular centre cell lymphoma (FCC) in 22 patients; (b) mantle cell lymphoma (MCL) in 10; (c) 1 diffuse large cell lymphoma (DLCL); and (d) the category of small lymphocytic lymphoma\/chronic lymphocytic leukaemia (SLL\/CLL) and related disorders in 15 patients. No patient obtained a complete remission. Ten patients (21%) achieved partial remission: 6 FCC, 2 MCL, 1 DLCL and 1 patient from the SLL\/CLL group. Twenty\u2010eight patients had stable disease and 10 progressed during immunotherapy. In patients with CLL and MCL in leukaemic phase, there was no correlation between the marked decrease in circulating neoplastic cells following antibody infusions and amelioration of the tumour burden. The results suggest that the subtype of LPD\/NHL and the intensity of CD20 on the tumour cells influence the effectiveness of IDEC\u2010C2B8. The antibody was most efficacious against FCC lymphoma. The efficacy (at the dose schedule of 375 mg\/m<jats:sup>2<\/jats:sup>\/wk \u00d7 4) against MCL and SLL\/CLL appeared to be limited, however.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T09:58:32Z","timestamp":1279447112000},"page":"76-82","source":"Crossref","is-referenced-by-count":135,"title":["IDEC\u2010C2B8 anti\u2010CD20 (Rituximab) immunotherapy in patients with low\u2010grade non\u2010Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients"],"prefix":"10.1111","volume":"62","author":[{"given":"D.T.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Amess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Doughty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hendry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.W.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199409000-00005"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.445"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.V73.3.651.651","article-title":"Treatment of B\u2010cell lymphomas with anti\u2010idiotype antibodies alone and in combination with alpha interferon","volume":"73","author":"Brown SL","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood.V80.6.1502.1502","article-title":"Monoclonal anti\u2010idiotype antibody therapy of B\u2010cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype\u2010negative variant cells","volume":"80","author":"Maloney DG","year":"1992","journal-title":"Blood"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood.V79.3.576.576","article-title":"Serotherapy of B\u2010cell neoplasms with anti\u2010B4 blocked ricin. A phase I trial of daily bolus infusion","volume":"79","author":"Grossbard ML","year":"1992","journal-title":"Blood"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308123290703"},{"key":"e_1_2_1_8_2","first-page":"1974","article-title":"Iodine\u2010131\u2010anti\u2010B1 radioimmunotherapy for B\u2010cell lymphoma","volume":"14","author":"Kaminski M","year":"1996","journal-title":"J Oncol"},{"key":"e_1_2_1_9_2","first-page":"457","article-title":"Ytrium labelled CD20 monoclonal anti\u2010CD20 therapy of recurrent B\u2010cell lymphoma","volume":"2","author":"Knox SI","year":"1996","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood.V82.9.2624.2624","article-title":"A phase I study of anti\u2010CD22\u2010deglycosylated ricin A chain immunotoxin in the treatment of B\u2010cell lymphomas resistant to conventional therapy","volume":"82","author":"Amlot PL","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199511000-00004"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.4.1188.bloodjournal8841188"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B\u2010cells in\u2010vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"82","author":"Reff ME","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_14_2","first-page":"637a","article-title":"The antitumor effect of monoclonal anti\u2010CD20 therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non\u2010Hodgkin's lymphoma cell lines","volume":"88","author":"Maloney DJ","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single\u2010dose infusion of chimeric anti\u2010CD20 monoclonal antibody (IDEC\u2010C2B8) in patients with recurrent B\u2010cell lymphomas","volume":"84","author":"Maloney DJ","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_16_2","first-page":"38","volume-title":"Clinical activity of the CD20 antibody, IDEC\u2010C2B8 (Rituximab), in clinically\u2010chemoresistant disease (CCRD) and other poor prognosis subgroups of low\u2010grade or follicular lymphoma (LG\/F NHL)","author":"Grillo\u2010Lopez AJ","year":"1997"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830400404"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4049\/jimmunol.135.2.973","article-title":"The B\u2010cell surface molecule B1 is functionally linked with B\u2010cell activation and differentiation","volume":"135","author":"Tedder TF","year":"1985","journal-title":"J Immunol"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.6.1766"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.4049\/jimmunol.135.6.3795","article-title":"The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to G1 phase of the cell cycle","volume":"135","author":"Goday JT","year":"1985","journal-title":"J Immunol"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830160802"},{"issue":"14","key":"e_1_2_1_24_2","first-page":"195","article-title":"The CD20 surface molecule of B lymphocytes functions as a calcium channel","author":"Tedder TF","year":"1990","journal-title":"J Cell Biochem"},{"issue":"2","key":"e_1_2_1_25_2","first-page":"S78","article-title":"Mantle cell lymphoma: a lymphoproliferative disorder associated with aberrant function of the cell cycle","volume":"10","author":"Garcia Conde J","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_1_26_2","first-page":"510a","article-title":"A multicenter, randomized phase II study of rituximab (chimeric anti\u2010CD20 mAb) at two dosages in patients with relapsed or refractory intermediate or high\u2010grade NHL (IHG\u2010NHL) or in elderly patients in first line therapy","volume":"90","author":"Coiffier B","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_27_2","first-page":"90a","article-title":"Pharmacokinetics (PK) and pharmacodynamics (PD) of the anti\u2010CD20 antibody (Mab) IDEC\u2010C2B8 in patients (pts) with relapsed low\u2010grade or follicular lymphoma (LG\/F NHL)","volume":"88","author":"McLaughin P","year":"1996","journal-title":"Blood"},{"issue":"1","key":"e_1_2_1_28_2","first-page":"56","article-title":"IDEC\u2010C2B8\/CHOP chemoimmunotherapy in patients with low\u2010grade lymphomas: Interim clinical and bcl\u20102 (PCR) results","volume":"7","author":"Czuczman MS","year":"1996","journal-title":"Ann Oncol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1999.tb01725.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1999.tb01725.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T12:43:36Z","timestamp":1698497016000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1999.tb01725.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,2]]}},"alternative-id":["10.1111\/j.1600-0609.1999.tb01725.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1999.tb01725.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,2]]}}}